U.S. group says Novartis MS drug price out of line with benefit

by reuter.com
http://bit.ly/pnED7n
A U.S. group that reviews the value of medicines issued a critical report on Novartis's new multiple sclerosis drug Mayzent, calling its $88,561 list price "far out of line" compared with its benefits for patients.

Read more

Share on Facebook Share on Twitter Share on Google Plus

About New

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.